Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer

European Journal of Cancer Part A

Volumn 33, Issue 9, 1997, Pages 1400-1406

  Soulie P ^a   Bensmaine A ^a   Garrino, C ^a   Chollet, P ^a   Brain, E ^a   Fereres, M ^a   Jasmin, C ^a   Musset, M ^a   Misset, J L ^a   Cvitkovic, E ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; OXALIPLATIN; TALLIMUSTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; GYNECOLOGIC CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KIDNEY DISEASES; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 0343247791     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00122-6     Document Type: Article

References (46)

1. Hole D, Gillis CR, Still RM, Davis J, Kaye SB. Medical audit-cancer registration and survival in ovarian cancer. Lancet 1991, 337, 611-612.
2. Kaye SB. Chemotherapy for ovarian cancer. Eur J Cancer 1993, 29, 632-635.
3. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992, 10, 706-717.
4. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334, 1-6.
5. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987, 5, 756-767.
6. Rothenberg ML, Ozols RF, Glatstein E, Steinberg SM, Reed E, Young RC. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol 1992, 10, 727-734.
7. Hainsworth JD, Burnett LS, Jones HW, Grosh WW, Johnson DH, Greco FA. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. J Clin Oncol 1990, 8, 502-508.
8. Piccart MJ, Nogaret JM, Marcelis L, Longrée H, Ries F, Kains JP. Cisplatin combined with carboplatin: A new way of intensification of platinum dose in the treatment of advanced ovarian cancer. J Natl Cancer Inst 1990, 82, 703-707.
9. Heron J, Kerbrat P, Mayer F, Chevallier B, Goupil A, Vennin P. Cisplatin (CDDP), carboplatin (CBDCA) and cyclophosphamide (CCPM) as first chemotherapy in advanced ovarian carcinoma (Stage IIIe-IV) with bulky residual disease. Proc Am Soc Clin Oncol 1992, 11, 223.
10. Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992, 340, 329-333.
11. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a gynecologic oncology group study. J Clin Oncol 1995, 13, 1589-1599.
12. Burchenal JH, Irani G, Kern K, Lokys L, Turkevich J. 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. In Mathé G, Muggia FM, eds. Recent Results in Cancer Research. 74. Berlin, Heidelberg, New York, Springer-Verlag. 1980, 146-155.
13. Myers TG, Paull KD, Fojo AT, et al. Multivariate analysis of high-flux screening data using the DISCOVER computer program package: integrated analysis of activity patterns and molecular structure features of platinum complexes. Proc Am As Can Res 1994, 35, 371 (abstract 2213).
14. Misset JL, Kidani Y, Gastiaburu J, Jasmin C, Léi F, Boughattas G. Oxalatoplatinum (1-OHP): experimental and clinical studies. In Howell SB, ed. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. New York, Plenum Press, 1991.
15. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993, 53, 5970-5976.
16. Alvarez M, Ortuzar W, Rixe O, Parker R, Reed E, Fojo T. Cross resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues. Proc Am As Can Res 1994, 35, 439 (abstract 2616.
17. Mathé G, Chenu E, Bourut C, Florentin I. Experimental study of three platinum complexes: CDDP, CBDCA and 1-OHP on L1210 leukemia. Alternate or simultaneous association of two platinum complexes. Proc Am As Can Res 1989, 30, 872.
18. Ortuzar W, Paull K, Rixe O, Fojo T. Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines. Proc Am As Can Res 1994, 35, 332.
19. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990, 25, 299-303..
20. Brienza S, Vignoud J, Itzhaki M. Oxaliplatin (L-OHP): Global safety in 682 patients. Proc. 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. 1995, Amsterdam (abstract 140).
21. Brienza S, Fandi A, Hugret F, Itzhaki M, Lecouturier S, Gastiaburu J. Neurotoxicity (NTX) of long term oxaliplatin (L-OHP). Proc Am As Can Res 1994, 34, 406.
22. Chollet P, Bensmaine MA, Brienza S, Deloche C, Curé H, Caillet H, Cvitkovic E. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996, 7, 1065-1070.
23. Markman M. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treatment population. J Clin Oncol 1992, 10, 513-514.
24. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
25. NCI Common Toxicity Criteria. National Cancer Institute, Division of Cancer Treatment, 1988.
26. Kelland LR. New platinum antitumor complexes. Crit Rev Oncol/Hematol 1993, 15, 191-219.
27. Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A. Phase I and pharmacokinetics study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 1994, 54, 709-717.
28. Weiss G, Green S, Alberts DS, Thigpen JT, Hines HE, Hanson K. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. Eur J Cancer (2) 1991, 27, 135-138.
29. Willemse PHB, Gietema JA, Mulder NH, de Vries EGE, Meijer S, Bouma J. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex. Eur J Cancer (3) 1993, 29A, 359-362.
30. Gietema JA, Veldhuis GJ, Guchelaar HJ, Willemse PHB, Uges DRA, Cats A. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. British J Cancer 1995, 71, 1302-1307.
31. Kavanagh JJ, Edwards CL, Freedman RS, et al. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecol Oncol 1995, 58, 106-109.
32. Markman M, Hakes T, Reichman B, et al. Ifosfamide and Mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992, 10, 243-248.
33. Schink JC, Harris LS, Grosen EA, Balley HH. Altretamine (Hexalen) an effective salvage chemotherapy after paclitaxel (Taxol) in women with recurrent platinum resistant ovarian cancer. Proc ASCO 1995, 14, 275 (abstract 770).
34. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to national cancer institute treatment referral center 9103. J Clin Oncol 1993, 11, 2405-2410.
35. Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Pazdur R, Bellet R. A Phase II trial of taxotere (RP 56976) in ovarian cancer patients refractory to cisplatin/carboplatin therapy. Proc Am Soc Clin Oncol 1993, 12, 259 (abstract 823).
36. Markman M, Rothman R, Hakes T, et al. Second-line Platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991, 9, 389-393.
37. Ozols RF, Ostchega Y, Myers CE, Young RC. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985, 3, 1246-1250.
38. 2) treatment in ovarian carcinoma. Br J Cancer 1992, 66, 717-719.
39. Gregg RW, Molepo JM, Monpetit VJA, Michael NZ, Gadia M, Stewart DJ. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992, 10, 795-803.
40. Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992, 69, 203-207.
41. Reed E, Janik J, Bookman MA, Rothenberg M, Smith K, Young RC. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. J Clin Oncol 1993, 11, 2118-2126.
42. ® comparative pharmacokinetics in normal and impaired renal function patients. Proc Am As Can Res 1994, 35, 242 (abstract 1445).
43. Gamelin E, Allain P, Delva R, Boisdron M, Meyer V, Brienza S. Study of long term cumulative pharmacokinetic characteristics of Oxaliplatin with inductively coupled plasma mass spectrometry. An open monocentric study of 17 patients. Proc Am Soc Clin Oncol 1996, 15, 471 (abstract 1488).
44. Garrino C, Cvitkovic E, Soulié P, et al. Preliminary report on the tolerance of transplatin (L-OHP) cisplatin (CP) association alone (Bi) or in combination with ifosfamide and epirubicin (Bic) in platinum pretreated patients. Proc ASCO 1994, 13, 143 (abstract 366).
45. Misset JL, Chollet Ph, Vennin Ph, et al. Decreased toxicity with oxaliplatin (LOHP) and cyclophosphamide in advanced ovarian cancer as compared to cisplatin and cyclophosphamide (P-C): Preliminary results of a multicentric Phase II-III trial. Ann Oncol (5) 1996, 7, 68 (abstract 3190).
46. Taamma A, Cvitkovic E, Soulié et al. Feasibility trial of the taxol, oxaliplatin (LOHP) and cisplatin (CDDP) combination in good prognosis recurrent ovarian cancer (ROC). Ann Oncol (5) 1996, 7, 75 (abstract 355P).